Investor Presentation - First Six Months of 2021

Higher profitability in the biopharm segment driven by lower S&D costs 120 Investor presentation First six months of 2021 Novo NordiskⓇ Diabetes and Obesity care P&L - full year 2020 Biopharm P&L - full year 2020 DKK DKK billion 120 billion -16% 100 -28% Sales ratios 20 -17% Sales ratios -16% 15 60 -10% 80 -3% +1% 55% 60 60 40 40 20 20 -13% -3% 10 0% 40% 5 0 0 Sales COGS S&D R&D Admin ΟΟΙ OP Sales COGS S&D R&D Admin ΟΟΙ OP P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit; S&D: Sales and distribution costs; R&D: Research and development costs; Admin: Administrative costs

View entire presentation